2023 World Conference on Lung Cancer (Posters)-EP14.03. Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy

EP14.03. Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy - PDF(Abstract)

Pdf Summary

Pulmonary blastoma (PB) is a rare form of lung cancer with no standard treatment. A case study presented at the WCLC 2023 conference showcased a successful treatment approach using immunotherapy and targeted therapy. The study team conducted a literature review and found 78 cases of PB, but only 9 had a positive response to chemotherapy. None of the cases in the literature used immunotherapy. <br /><br />In this particular case, a 35-year-old woman presented with a cough and sputum. CT scans revealed an irregular mass in the lower lobe of the left lung, and a filling defect in the left atrial pulmonary vein side. Biopsy results indicated adenocarcinoma with components of fetal adenocarcinoma or PB. The patient was not eligible for surgery and declined conventional chemoradiotherapy. After consultation with a multidisciplinary team, she received 8 cycles of anlotinib (a multikinase inhibitor) and penpulimab (an anti-PD-1 monoclonal antibody). Eight months later, the tumor significantly reduced in size, and a lobectomy was performed. The pathology report showed residual PB with minimal tumor cells and fibrosis. No metastasis was found in the dissected lymph nodes. The patient continues to receive penpulimab as postoperative immune maintenance therapy and is being followed up.<br /><br />This case study suggests that the combination of immunotherapy and targeted therapy could be an effective treatment strategy for PB. It may produce a more significant clinical response or even a synergistic effect. The study emphasizes considering this approach as a potential therapeutic strategy for PB.

Asset Subtitle

Yongmei Liu

Meta Tag

Speaker Yongmei Liu

Topic Other Thoracic Malignancy

Keywords

Pulmonary blastoma

lung cancer

rare form

standard treatment

immunotherapy

targeted therapy

case study

WCLC 2023 conference

chemotherapy response

literature review